Tech Company Financing Transactions
Anokion Funding Round
On 10/18/2022, Anokion secured $35 million in funding from Pfizer Venture Investments.
Transaction Overview
Company Name
Announced On
10/18/2022
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use a portion of the proceeds to fund its Phase 2 clinical program of KAN-101 for the treatment of individuals with celiac disease, a serious autoimmune disorder triggered by ingestion of gluten, for which there are no approved therapeutic treatments available.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
50 Hampshire St. 4th floor 402
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Anokion SA (including our wholly-owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary antigen-specific immune tolerance technology is designed to be both more effective and specific than the current standard of care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Deborah Geraghty
Chief Scientific Officer
Stephan Kontos
Controller
Hilda Buehler
VP - Bus. Development
Raj Manchanda
Browse more venture capital transactions:
Prev: 10/18/2022: Raito venture capital transaction
Next: 10/18/2022: Navro venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs